Lundin A - Search Results

1

Dopamine D1 receptor number--a sensitive PET marker for early brain degeneration in Huntington's disease.

Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, Farde L. Sedvall G, et al. Among authors: lundin a. Eur Arch Psychiatry Clin Neurosci. 1994;243(5):249-55. doi: 10.1007/BF02191583. Eur Arch Psychiatry Clin Neurosci. 1994. PMID: 8172940

2

PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.

Ginovart N, Lundin A, Farde L, Halldin C, Bäckman L, Swahn CG, Pauli S, Sedvall G. Ginovart N, et al. Among authors: lundin a. Brain. 1997 Mar;120 ( Pt 3):503-14. doi: 10.1093/brain/120.3.503. Brain. 1997. PMID: 9126061

3

Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes.

Bäckman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Bäckman L, et al. Among authors: lundin a. Brain. 1997 Dec;120 ( Pt 12):2207-17. doi: 10.1093/brain/120.12.2207. Brain. 1997. PMID: 9448576

4

A Huntington disease-like neurodegenerative disorder maps to chromosome 20p.

Xiang F, Almqvist EW, Huq M, Lundin A, Hayden MR, Edström L, Anvret M, Zhang Z. Xiang F, et al. Among authors: lundin a. Am J Hum Genet. 1998 Nov;63(5):1431-8. doi: 10.1086/302093. Am J Hum Genet. 1998. PMID: 9792871 Free PMC article.

5

Larger CAG expansions in skeletal muscle compared with lymphocytes in Kennedy disease but not in Huntington disease.

Ansved T, Lundin A, Anvret M. Ansved T, et al. Among authors: lundin a. Neurology. 1998 Nov;51(5):1442-4. doi: 10.1212/wnl.51.5.1442. Neurology. 1998. PMID: 9818876

6

Reactions to predictive testing in Huntington disease: case reports of coping with a new genetic status.

Wahlin TB, Lundin A, Bäckman L, Almqvist E, Haegermark A, Winblad B, Anvret M. Wahlin TB, et al. Among authors: lundin a. Am J Med Genet. 1997 Dec 19;73(3):356-65. doi: 10.1002/(sici)1096-8628(19971219)73:3<356::aid-ajmg24>3.0.co;2-h. Am J Med Genet. 1997. PMID: 9415699

7

High suicidal ideation in persons testing for Huntington's disease.

Robins Wahlin TB, Bäckman L, Lundin A, Haegermark A, Winblad B, Anvret M. Robins Wahlin TB, et al. Among authors: lundin a. Acta Neurol Scand. 2000 Sep;102(3):150-61. doi: 10.1034/j.1600-0404.2000.102003150.x. Acta Neurol Scand. 2000. PMID: 10987374

8

Early cognitive deficits in Swedish gene carriers of Huntington's disease.

Robins Wahlin TB, Lundin A, Dear K. Robins Wahlin TB, et al. Among authors: lundin a. Neuropsychology. 2007 Jan;21(1):31-44. doi: 10.1037/0894-4105.21.1.31. Neuropsychology. 2007. PMID: 17201528

9

Olfactory functions in asymptomatic carriers of the Huntington disease mutation.

Larsson M, Lundin A, Robins Wahlin TB. Larsson M, et al. Among authors: lundin a. J Clin Exp Neuropsychol. 2006 Nov;28(8):1373-80. doi: 10.1080/13803390500473746. J Clin Exp Neuropsychol. 2006. PMID: 17050264

10

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.

Lundin A, Dietrichs E, Haghighi S, Göller ML, Heiberg A, Loutfi G, Widner H, Wiktorin K, Wiklund L, Svenningsson A, Sonesson C, Waters N, Waters S, Tedroff J. Lundin A, et al. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. doi: 10.1097/WNF.0b013e3181ebb285. Clin Neuropharmacol. 2010. PMID: 20616707 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

395 results

Search Page

Filters